angiotensin ii, des-phe(8)- has been researched along with 20-hydroxy-5,8,11,14-eicosatetraenoic acid in 1 studies
Studies (angiotensin ii, des-phe(8)-) | Trials (angiotensin ii, des-phe(8)-) | Recent Studies (post-2010) (angiotensin ii, des-phe(8)-) | Studies (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Trials (20-hydroxy-5,8,11,14-eicosatetraenoic acid) | Recent Studies (post-2010) (20-hydroxy-5,8,11,14-eicosatetraenoic acid) |
---|---|---|---|---|---|
1,533 | 21 | 995 | 640 | 13 | 233 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carroll, MA; Chander, PN; Kang, Y; Stier, CT | 1 |
1 other study(ies) available for angiotensin ii, des-phe(8)- and 20-hydroxy-5,8,11,14-eicosatetraenoic acid
Article | Year |
---|---|
Azilsartan is associated with increased circulating angiotensin-(1-7) levels and reduced renovascular 20-HETE levels.
Topics: Angiotensin I; Animals; Benzimidazoles; Blood Pressure; Disease Models, Animal; Hydroxyeicosatetraenoic Acids; Hypertension; Hypertension, Renovascular; Male; Oxadiazoles; Peptide Fragments; Rats; Rats, Sprague-Dawley; Vasoconstriction | 2015 |